Legal & General Group PLC Checkpoint Therapeutics, Inc. Transaction History

Legal & General Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$2.36 - $3.2 $14,927 - $20,240	-6,325 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$2.6 - $4.16 $115,068 - $184,109	-44,257 Reduced 87.5%	6,325 $20,000
Q4 2020 Feb 12, 2021	BUY	$2.19 - $2.96 $99,426 - $134,384	45,400 Added 876.11%	50,582 $134,000
Q3 2020 Nov 13, 2020	SELL	$1.62 - $4.24 $3,154 - $8,255	-1,947 Reduced 27.31%	5,182 $14,000
Q2 2020 Aug 14, 2020	BUY	$1.19 - $2.27 $2,587 - $4,934	2,174 Added 43.87%	7,129 $14,000
Q4 2019 Feb 13, 2020	BUY	$1.18 - $2.39 $1,296 - $2,626	1,099 Added 28.5%	4,955 $9,000
Q2 2019 Aug 14, 2019	BUY	$2.75 - $5.0 $10,604 - $19,280	3,856 New	3,856 $13,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $351M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.